Rheumatoid Arthritis Patients at Risk for Interstitial Lung Disease

  • STATUS
    Recruiting
  • End date
    Jun 24, 2027
  • participants needed
    500
  • sponsor
    University of Colorado, Denver
Updated on 24 February 2021
pulmonary disease
pulmonary fibrosis
fibrosis
idiopathic pulmonary fibrosis
interstitial lung disease

Summary

The overall goal of this study is to define the phenotype of Interstitial Lung Disease (ILD) in patients with rheumatoid arthritis (RA). The investigators hypothesize that there are common elements between other forms of ILD such as idiopathic pulmonary fibrosis (IPF) and sub-clinical RA-ILD that places individuals at risk for the development of lung disease.

This is not a treatment study. It is a protocol designed to enroll individuals affected by RA and explore associated lung disease so that the investigators can better understand the clinical phenotype and genetic and molecular endotypes of this disease.

Details
Condition Pulmonary Disease, Lung Disease, Rheumatoid Arthritis, Rheumatoid Arthritis, Rheumatoid Arthritis (Pediatric), Pulmonary Fibrosis, Pulmonary Fibrosis, Interstitial lung disease, Rheumatoid Arthritis (Pediatric), Lung Disease, interstitial lung diseases
Clinical Study IdentifierNCT03297775
SponsorUniversity of Colorado, Denver
Last Modified on24 February 2021

Eligibility

Yes No Not Sure

Inclusion Criteria

Diagnosis of RA using the 2010 American College of Rheumatology (ACR) criteria

Exclusion Criteria

Inability to give informed consent
Pregnant women
History of Interstitial Lung Disease
Evidence of other cause of diffuse parenchymal lung disease such as infection, drug toxicity, other autoimmune processes, etc
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

0/250

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note